title: Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation.
abstract: There is a growing interest in the evaluation of non-myeloablative conditioning therapy for allogeneic stem cell transplantation. Such regimens are expected to produce less toxicity while allowing both engraftment and a graft-versus-disease effect from the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. Heavy immunosuppression used in recipients may have unexpected consequences. We describe the occurrence of a fatal Epstein-Barr virus-associated B cell lymphoproliferative disease (BLPD) early after such a non-myeloablated allogeneic peripheral blood stem cell transplant in a heavily pretreated patient.
authors.affiliation: Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: M
authors.initials: M
authors.lastname: Coste-Burel
authors.forename: F
authors.initials: F
authors.lastname: Accard
authors.forename: A
authors.initials: A
authors.lastname: Moreau
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: R
authors.initials: R
authors.lastname: Garand
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000328:Adult; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000821:virology; D019653:Myeloablative Agonists / Q000627:therapeutic use; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D019653:Myeloablative Agonists